Hirudin inhibits glioma growth through mTOR‐regulated autophagy

Abstract

AbstractGlioma is the most common primary malignant brain tumour, and survival is poor. Hirudin has anticancer pharmacological effects through suppression of glioma cell progression, but the molecular target and mechanism are poorly understood. In this study, we observed that hirudin dose‐ and time‐dependently inhibited glioma invasion, migration and proliferation. Mechanistically, hirudin activated LC3‐II but not Caspase‐3 to induce the autophagic death of glioma cells by decreasing the phosphorylation of mTOR and its downstream substrates ULK1, P70S6K and 4EBP1. Furthermore, hirudin inhibited glioma growth and induced changes in autophagy in cell‐derived xenograft (CDX) nude mice, with a decrease in mTOR activity and activation of LC3‐II. Collectively, our results highlight a new anticancer mechanism of hirudin in which hirudin‐induced inhibition of glioma progression through autophagy activation is likely achieved by inhibition of the mTOR signalling pathway, thus providing a molecular basis for hirudin as a potential and effective clinical drug for glioma therapy.